NASDAQ: ENTAEnanta Pharmaceuticals Inc Stock
$12.92-0.23 (-1.75%)
Updated Apr 24, 2024
ENTA Price
$12.92
Fair Value Price
-$8.52
Market Cap
$273.34M
52 Week Low
$8.08
52 Week High
$37.75
P/E
-1.97x
P/B
1.42x
P/S
2.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$73.62M
Earnings
-$138.24M
Gross Margin
100%
Operating Margin
-173.07%
Profit Margin
-187.8%
Debt to Equity
1.23
Operating Cash Flow
-$93M
Beta
0.9
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ENTA Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENTA ($12.92) is overvalued by 251.71% relative to our estimate of its Fair Value price of -$8.52 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ENTA ($12.92) is not significantly undervalued (251.71%) relative to our estimate of its Fair Value price of -$8.52 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ENTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENTA due diligence checks available for Premium users.
Be the first to know about important ENTA news, forecast changes, insider trades & much more!
ENTA News
Valuation
ENTA fair value
Fair Value of ENTA stock based on Discounted Cash Flow (DCF)
Price
$12.92
Fair Value
-$8.52
Undervalued by
251.71%
ENTA ($12.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENTA ($12.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.97x
Industry
15.69x
Market
41.27x
ENTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
5.86x
ENTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENTA's financial health
Profit margin
Revenue
$18.0M
Net Income
-$33.4M
Profit Margin
-185.6%
ENTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ENTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$428.5M
Liabilities
$236.6M
Debt to equity
1.23
ENTA's short-term assets ($390.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENTA's short-term assets ($390.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ENTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.0M
Investing
-$13.1M
Financing
-$7.4M
ENTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENTA vs Biotech Stocks
Enanta Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.